Abstracts tagged "B-Lymphocyte"

Abstract Number: 0105 • ACR Convergence 2023
Characterization of B-Cell Subsets in Antiphospholipid Syndrome Patients: Implications for Disease Phenotype and Pathogenesis
Yin Long¹, Jiuliang zhao², Mengtao Li² and Xiaofeng Zeng², ¹Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology, Beijing, China, ²Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Primary antiphospholipid syndrome (PAPS) is an autoimmune disorder characterized by the presence of pathogenic autoantibodies. The key immune cell subsets change in PAPS patients…
Abstract Number: 1227 • ACR Convergence 2023
Serious Infections Following Rituximab Administration in Children with Systemic Lupus Erythematosus
Jordan Roberts¹, Anna Faino², Mersine Bryan¹, Jonathan Cogen¹ and Esi Morgan¹, ¹Seattle Children's Hospital, Seattle, WA, ²Seattle Children’s Research Institute, Seattle, WA
Background/Purpose: Rituximab has been associated with high rates of infection among adults with systemic lupus erythematosus. However, studies of infection risk following rituximab among children…
Abstract Number: 0212 • ACR Convergence 2023
The Impact of Immunosuppression on the Humoral Immunogenicity of SARS-CoV-2 mRNA Vaccines in SLE
Rebecca Sadun¹, Dan Crair², Emmanuel B Walter³, Jennifer Rogers¹, Megan Clowse⁴, Amanda Eudy⁵, Kai Sun¹, Jayanth Doss¹, Lisa Criscione-Schreiber⁶, Sarah Valencia² and M. Anthony Moody⁶, ¹Duke University, Durham, NC, ²Duke Human Vaccine Institute, Durham, NC, ³Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, ⁴Duke University, Chapel Hill, NC, ⁵Duke University, Raleigh, NC, ⁶Duke University School of Medicine, Durham, NC
Background/Purpose: The ACR's COVID-19 Vaccine Guidance recommends all patients with rheumatic diagnoses be vaccinated against SARS-CoV-2. The predominant SARS-CoV-2 vaccines used in the United States…
Abstract Number: 1370 • ACR Convergence 2023
Synthetic Glabridin Derivatives Improves Sjogren’s Syndrome by Inducing Salivary Secretion and Salivary Gland Regeneration
Eui-Jong Kwon¹, Jin-Sil Park², Ha Yeon Jeong³, Hye Yeon Kang⁴, JeongWon Choi³, Mi-La Cho³ and Sung-Hwan Park⁵, ¹Division of Rheumatology, Department of Internal Medicine, The Catholic University of Korea Seoul St. Mary's Hospital, Seocho-gu, South Korea, ²The Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seocho-gu, South Korea, ³Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁴Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seocho-gu, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Sjogren’s syndrome (SS) is a systemic autoimmune disease characterized by infiltration of lymphocytes into the exocrine gland resulting in progressive lacrimal and salivary estruction…
Abstract Number: 0274 • ACR Convergence 2023
A Mix-and-match COVID-19 Vaccination Strategy in Patients with Rheumatic Diseases on Rituximab
Nathalie Amiable¹, Mehdi Benlarbi², Mathieu Dube³, Sonia Theriault⁴, Alexandra Godbout¹, Anne-Sophie Julien⁵, Gloria-Gabrielle Ortega-Delgado⁶, Melina Duchesne⁷, Rose Cloutier⁸, Josee Perreault⁹, Annie Gravel¹⁰, Lison Fournier¹¹, Giuliana Alfonso¹², Josiane Bourre-Tessier¹³, Marie Hudson¹⁴, Nicolas Richard¹⁵, Jean-Paul Makhzoum¹⁶, Arielle Mendel¹⁷, Sasha Bernatsky¹², Marc Dionne¹⁸, Michael Libman¹⁹, Gaston De Serres²⁰, Mélanie Dieudé²¹, louis Flamand²², Daniel Kaufmann²³, Andrés Finzi²⁴, Renée Bazin²⁵, Ines Colmegna²⁶ and Paul R. Fortin²⁷, ¹Centre ARThrite - CHU de Quebec - Universite Laval, Quebec City, QC, Canada, ²CRCHUM, Université de Montréal, Montreal, QC, Canada, ³Centre de recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada, ⁴The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁵Département de mathématiques et statistique, Université Laval, Québec, QC, Canada, ⁶Centre de Recherche du CHUM, Montreal, QC, Canada, ⁷Centre de recherche du Centre Hospitalier de l'Universitaire de Montréal, Montreal, QC, Canada, ⁸Centre de recherche hospitalier de l'Université de Montréal, Montreal, QC, Canada, ⁹Hema-Quebec, Quebec City, QC, Canada, ¹⁰CHU de Québec - CHUL Axe des Maladies Infectieuses et Immunitaires, Quebec City, QC, Canada, ¹¹Centre de recherche du CHU de Quebec - Université Laval, Quebec City, QC, Canada, ¹²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹³Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada, ¹⁴McGill University, Montréal, QC, Canada, ¹⁵Hopital Maisonneuve Rosemont, Montreal, QC, Canada, ¹⁶Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ¹⁷McGill University Health Centre, Montréal, QC, Canada, ¹⁸Centre de recherche du CHU de Québec - Université Laval, Quebec City, QC, Canada, ¹⁹McGill Centre for Viral Diseases, Montreal, QC, Canada, ²⁰Centre de recherche du CHU de Québec – Université Laval, Quebec City, QC, Canada, ²¹Microbiology, Infectiology and Immunology Department, Faculty of Medicine, Université de Montréal, CHUM Research Center, Héma-Québec, Montreal, QC, Canada, ²²Centre ARThrite - CHU de Quebec - Université Laval, Quebec City, QC, Canada, ²³University of Montreal, University of Lausanne, Lausanne University Hospital, Montreal, QC, Canada, ²⁴Université de Montréal, Montreal, QC, Canada, ²⁵Héma-Québec, Affaires Médicales et Innovation, Quebec City, QC, Canada, ²⁶The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²⁷Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada
Background/Purpose: Patients with rheumatic diseases (RD) on rituximab (RTX) have increased mortality following COVID-19 and reduced antibody response post-vaccine. We tested whether a mix-and-match strategy…
Abstract Number: 1458 • ACR Convergence 2023
Activated Naïve DNA-Reactive B Cells in Lupus Nephritis Patients Are Increased and Associated with Disease Activity
Kittikorn Wangriatisak¹, Francesca Faustini², Charlotte de Vries³, Ravi Kumar Sharma⁴, Caroline Grönwall⁵, Prapaporn Pisitkun⁶, Patchanee Chootong⁷, Vivianne Malmström⁵ and Iva Gunnarsson⁸, ¹Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Thailand ; Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ²Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Medicine Unit Dermatology, Gastroenterology, Rheumatology; unit of Rheumatology, Karolinska University Hospital Solna, Stockholm, Sweden, ³Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶Division of Allergy Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bankok, Thailand, ⁷Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Bangkok, Thailand, ⁸Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Medicine Unit Dermatology, Gastroenterology, Rheumatology; unit of Rheumatology, Karolinska University Hospital Solna, Sweden, Stockholm, Sweden
Background/Purpose: Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE), which is characterized by abnormal B-cell activation and their…
Abstract Number: 0440 • ACR Convergence 2023
Baseline T Cell and B Cell-related Markers and HLA-DRB1 Shared Epitope Alleles Predict the Therapeutic Efficacy of Abatacept in Patients with Moderate to Severe Rheumatoid Arthritis
Ting Wang¹, Natalia V. Giltiay², Christian Lood² and Bobby Kwanghoon Han², ¹University of Washington, Seattle, WA, ²Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Abatacept, a CTLA-4-Ig fusion protein, is widely used as a treatment for rheumatoid arthritis (RA). However, data on predictive biomarkers associated with therapeutic response…
Abstract Number: 1602 • ACR Convergence 2023
NADPH Oxidase Exerts a B Cell-intrinsic Contribution to Lupus Risk by Modulating Endosomal Toll-like Receptor (TLR) Signals
Shuozhi Liu¹, Natali Shumlak¹, Andrea Largent¹, Sebastien Lewis¹, Mridu Acharya¹ and Shaun Jackson², ¹Seattle Children's Research Institute, Seattle, WA, ²Seattle Children's Research Institute / University of Washington, Seattle, WA
Background/Purpose: Genome-wide association studies in systemic lupus erythematosus (SLE) have linked loss-of-function mutations in phagocytic NADPH oxidase complex (NOX2) genes, including NCF1 and NCF2, to…
Abstract Number: 0577 • ACR Convergence 2023
Analysis of Intracytoplasmic Toll – Like Receptors (TLRs) and MyD88 Expression in B Cell Subsets in Patients with Lupus Nephritis
Michelle Patricia Loeza-Uribe¹, Michelle Nicolle Espinoza-Carranza¹, Yatzil Reyna-Juárez¹, Beatriz Alcalá-Carmona¹, Nancy Raquel Mejía-Domínguez², Guillermo Juárez-Vega², José Luis Maravillas-Montero², Karina Santana-de Anda¹, José Jiram Torres-Ruiz¹ and Diana Gómez-Martín¹, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán and Universidad Nacional Autónoma de México, Mexico City, Mexico
Background/Purpose: Intrinsic signaling of intracytoplasmic TLRs (7 and 9) and MyD88 in B cells (BC) plays an important role in the development and pathogenesis of…
Abstract Number: 1813 • ACR Convergence 2023
Assessing Immunogenicity of SARS-CoV-2 Vaccine Neoantigen S1 in Autoimmune Rheumatic Disease Patients: A Study on Cellular and Humoral Responses
Inés Pérez Sancristóbal¹, Maria Paula Alvarez Hernandez¹, kauzar Mohamed Mohamed², Maria Rodriguez Laguna¹, Cristina Martinez³, Esther Toledano³, Dalifer Freites⁴, Benjamin Fernandez¹, María Rodero³, Cecilia Bravo³, Antonia Rodrígez de la Peña⁵, Silvia Sanchez - Ramon⁵, Gloria mato Chain⁶ and Gloria Candelas¹, ¹Hospital Clinico San Carlos, Madrid, Spain, ²Department of Immunology, Hospital Clínico San Carlos, Madrid, Spain, ³Hospital Clinico San Carlos, Rheumatology Deparment, Madrid, Spain, ⁴Hospital Clínico San Carlos, Madrid, Spain, ⁵Department of Clinical Immunology, IML and IdSSC, Hospital Clínico San Carlos, Madrid, Spain, ⁶Department of Preventive Medicine, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: Data on cellular and humoral immunogenicity triggered by SARS-CoV-2 vaccines in patients with autoimmune rheumatic diseases (ARD) are limited. While current vaccine efforts have…
Abstract Number: 0589 • ACR Convergence 2023
A Comparative Evaluation of IgA2 Anti-dsDNA Antibodies and Clinical Outcome in Two Clinical Trials of Belimumab After Rituximab in SLE
Muhammad RA Shipa¹, Daniel McCluskey¹, Laura Cooney² and Michael Ehrenstein¹, ¹University College London, London, United Kingdom, ²Immune Tolerance Network, Seattle, WA
Background/Purpose: We have shown that serum IgA2 anti-dsDNA antibody levels is a biomarker of response to belimumab after rituximab in SLE (BEAT-lupus trial) (1). We…
Abstract Number: 2124 • ACR Convergence 2023
Expansion of Atypical B Cells Accompanies Rheumatoid Arthritis-like Immune Dysregulation in ACPA+ At-risk Individuals
Adam Savage¹, Ziyuan He¹, Marla Glass¹, Julian Reading¹, LauraKay Moss², Marie Feser², Vlad Tsaltskan³, Katherine Nguyen Nguyen³, Kristen Demoruelle², kristine Kuhn⁴, David Boyle³, Cate Speake⁵, Xiao-Jun Li¹, Peter Skene¹, Troy Torgerson¹, Tom Bumol¹, V. Michael Holers⁶, Jane Buckner⁷, Gary Firestein⁸, kevin Deane² and Mark Gillespie¹, ¹Allen Institute for Immunology, Seattle, WA, ²University of Colorado Anschutz Medical Campus, Aurora, CO, ³University of California San Diego, La Jolla, CA, ⁴University of Colorado School of Medicine, Aurora, CO, ⁵Benaroya Research Institute, Seattle, WA, ⁶University of Colorado, Denver, CO, ⁷Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁸University of California San Diego, San Diego, CA
Background/Purpose: Seropositive RA is preceded by an at-risk stage characterized by elevated circulating autoantibodies (AAb), including ACPA, in otherwise healthy individuals without clinically-apparent inflammatory arthritis.…
Abstract Number: 0607 • ACR Convergence 2023
CAR T Cell Therapy Leads to Long-term Abrogation of Autoimmunity in SLE Patients While Vaccination Responses Are Maintained
Georg Schett¹, Luis Munoz², Jule Taubmann³, Michael Aigner⁴, Christina Bergmann⁵, Johannes Knitza⁶, Gerhard Kroenke⁷, Dagmar Werner², Fabian Müller⁸ and Andreas Mackensen⁴, ¹Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ²FAU Erlangen-Nürnberg, Erlangen, Germany, ³Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁴Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁵Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁶Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ⁷Charite Berlin, Berlin, Germany, ⁸Friedrich Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: We have previously shown that CD19 CAR T cell therapy leads to stable drug-free remission of treatment-resistant SLE (1,2). Based on these findings we…
Abstract Number: 2189 • ACR Convergence 2023
Lymphopenia Fluctuation Patterns Determine the Trajectory of the Disease in Sjogren’s Patients with Hematological Involvement
Giovanni Fulvio¹, Matilde Bandeira², Augusto Silva³, Gaetano La Rocca⁴, Silvia Fonzetti⁵, Francesco Ferro⁶, Marta Mosca⁷, Vasco Romão², Chiara Baldini¹, Manuel Silvério-António⁸ and Nikita Khmelinskii², ¹University of Pisa, Pisa, Italy, ²Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ³Santa Maria Hospital, Maceira, Portugal, ⁴University of Pisa, Rheumatology Unit, Pisa, Italy, ⁵AOUP, Pisa, Italy, ⁶Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ⁷Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ⁸Hospital Santa Maria, Lisboa, Portugal
Background/Purpose: Sjogren's disease (SjD) is characterized by a moderate prevalence of cytopenia, mainly neutropenia and lymphocytopenia with a typical fluctuating pattern. The associations between clinical…
Abstract Number: 0728 • ACR Convergence 2023
Systemic Lupus Erythematosus B Lymphocyte Responsiveness to Type I and Type III Interferon Is Determined by Donor IFN Status and B Cell Phenotype
Diana Alzamareh, Mary O'Connell, Jennifer Anolik and Jennifer Barnas, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Systemic lupus erythematous (SLE) is a heterogenous autoimmune disorder characterized by pathogenic antinuclear antibodies. An interferon (IFN) gene signature and B cell aberrations are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].